Better Energy Stock: Oklo vs. Centrus Energy

Nuclear power is seeing renewed investor and regulatory support, with Oklo and Centrus Energy rallying 365% and 252% respectively over the past year versus the S&P 500's 13% gain. Oklo, founded in 2013, is developing the Aurora small modular reactor (15–75 MWe initially) but has no commercial units or binding customers and targets first operation in late 2027/early 2028. Centrus, an established LEU supplier that generates current revenue, holds an NRC license to produce HALEU and relies today on imports (including a DOE-waived Russian TENEX agreement for 2026–27); it must expand enrichment capacity at Piketon and secure DOE funding and long-term contracts to transition to domestic LEU/HALEU production. Given near-term revenue and regulatory positioning, Centrus is presented as the more investable pick today while Oklo remains higher risk/longer horizon.

Analysis

Market structure: The near-term winners are enrichment-services and fuel suppliers (Centrus/LEU, Cameco/CCJ, spot uranium ETFs) and utilities signing long-term offtakes; losers include Russian TENEX-linked supply chains and early-stage reactor equities without revenue (OKLO). Pricing power will shift toward licensed domestic enrichment capacity as a ~25% Russia-origin LEU gap phases in by 2028, which should lift enrichment service margins and spot LEU/uranium prices by perhaps 30–70% if replacement capacity lags demand growth (35 GW by 2035 target).

Risk assessment: Key tail risks are NRC licensing delays or a high-profile operational failure that stalls SMR approvals, and a DOE funding shortfall for Piketon — each could erase >50% upside in early-cycle names. Time horizons differ: market reactions in days–months to funding or contract announcements, material production/outcome impact in 2027–2032. Hidden dependencies include supply-chain bottlenecks for HALEU hardware and political shifts on nuclear subsidies.

Trade implications: Favor LEU exposure (LEU stock or enrichment-service names) with a 2–4% portfolio allocation, and treat OKLO as a binary longer-dated optionality vehicle (small call positions or <1% equity). Use pair trades: long LEU vs short OKLO to neutralize macro beta; use options — buy 2029 LEAPS on OKLO (cheap asymmetric upside) and sell near-term LEU covered calls post positive DOE/contract news to harvest premium.

Contrarian angles: Consensus underrates the pace at which enrichment pricing will rise once Russian volumes drop — this is a supply-inelastic choke point. Conversely, optimism on SMR placement timelines may be overdone: expect 12–36 month slippage risk meaningfully compresses OKLO equity upside until licensing and firm PPAs are secured. Historical parallel: reactor ramp cycles (1970s–80s) show multi-year lumpy capex and regulatory risk, not steady linear adoption.

Key Decisions for Investors

• Establish a 2–4% long position in Centrus Energy (LEU) within 30–90 days, target 30–60% upside on successful DOE funding or 1–2 HALEU customer contracts; set a hard stop at -20% on negative DOE/contract outcomes.
• Open a dollar-neutral pair: long $1.0m LEU vs short $1.0m OKLO (OKLO) to capture relative re-rating; trim the short if OKLO falls >40% or if LEU prints DOE funding confirmation.
• Allocate 0.5–1.0% of portfolio to long-dated OKLO call LEAPS (expiry 12/31/2029) as asymmetric optionality; cap allocation due to binary licensing/operational risk.
• Sell 1–3 month covered calls on LEU after any positive DOE or off-take announcement to monetize elevated IV; use strikes ~10% above post-news price to balance upside capture and premium.
• Monitor three catalysts as trade triggers: DOE Piketon funding decision (within next 90 days), any NRC substantive interactions or license milestones for OKLO (quarterly), and announced HALEU offtake contracts (next 6–18 months); adjust positions +/-50% around these events.